|Bid||6,877.00 x 0|
|Ask||6,881.00 x 0|
|Day's Range||6,791.48 - 6,952.00|
|52 Week Range||5,312.00 - 7,583.00|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||40.25|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||2.19 (3.22%)|
|1y Target Est||78.83|
AstraZeneca today announced that the US Food and Drug Administration has granted Fast Track designation for the development of FARXIGA to reduce the risk of cardiovascular death or the worsening of heart failure in adults with heart failure with reduced ejection fraction or preserved ejection fraction .
The U.S. Food and Drug Administration (FDA) granted the status for development of the drug to reduce the risk of deadly heart attacks and disease progression in adults with the HFrEF and HFpEF subtypes of heart failure, the British drugmaker said on Monday. Farxiga, already approved as a treatment for type-2 diabetes, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.
The company has burned through $400 million, laid off employees and lost two Big Pharma partnerships, but now it is near an FDA drug approval for people with a debilitating bowel disorder.
In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone
AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs. Patients in a reference group on chemotherapy only lived a median 10.3 months in the so-called Caspian trial, it said. "There is a wide recognition that in small cell lung cancer there is very much a need for new therapies," said Dave Fredrickson, head of the company's oncology business.
It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators' hands.
Roche, Spark, AstraZeneca, Snap, Walmart and eBay are the companies to watch
The biotech space saw muted activity in the week ended Aug. 30. Among the notable news of the week: Amgen, Inc. (NASDAQ: AMGN )'s $13.4-billion deal to buy the psoriasis drug Otezla from Celgene Corporation ...
Gaithersburg-based Viela Bio Inc. has filed to begin trading publicly with a $150 million initial public offering, fast bringing the business full circle after its spinout from MedImmune in early 2018. The biotech applied to trade on the Nasdaq Global Market under the ticker symbol "VIE" and plans to offer a little more than 37 million shares to the public, including 393,780 shares of unvested restricted stock subject to repurchase.
The IPO market, which has been in a lull in recent weeks, is likely to pick up steam just in time for a year-end push. Gaithersburg, Maryland-based Viela Bio, Inc., an AstraZeneca plc (NYSE: AZN ) spin-off, ...
AstraZeneca today announced positive results from the Phase III ETHOS trial for triple-combination therapy PT010 in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
Prospects for AstraZeneca's respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker's lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition. AstraZeneca said the late-stage ETHOS trial of triple-drug therapy Breztri Aerosphere, formerly known as PT010, helped patients suffering from chronic obstructive pulmonary disease (COPD), in a challenge to Glaxosmithkline’s Trelegy Ellipta.
Gaithersburg’s Viela Bio Inc. has crossed another milepost in its race to get its first drug to market. The fast-moving biotech has submitted its formal application to the Food and Drug Administration to get approval to start marketing inebilizumab, its candidate for neuromyelitis optica spectrum disorder, a rare autoimmune disease that compromises the central nervous system. Under that timeline, pending approval, Viela could get the drug to patients by early next year.
AstraZeneca today announced that the US Food and Drug Administration has granted Fast Track designation for the development of FARXIGA to delay the progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease .
AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease (CKD). Farxiga, one of AstraZeneca's top 10 drugs by sales, is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.
Benzinga has examined the prospects for many investor favorite stocks over the past week. It was another tough week for the markets, with the Dow Jones industrials and the S&P 500 dropping 2% or so and the Nasdaq more than 3% lower when all was said and done. The trade war with China ratcheted up again and commentary from Federal Reserve Chair Jerome Powell did not please the president (who apparently still wants to buy Greenland).
Sep.09 -- AstraZeneca PLC is betting on sales of its new drug to outweigh that of off-patient ones in China over the next five years amid Chinese regulator's expedited approval of new therapies to meet unmet medical demands. Leon Wang, it's executive vice president overseeing international markets, spoke exclusively to Selina Wang on "Bloomberg Daybreak: Asia.